Claims for Patent: 8,283,382

Summary for Patent: 8,283,382

Title:	Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy
Abstract:	The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
Inventor(s):	Perez-Soler; Roman (New York, NY), Ling; Yi-He (Briarwood, NY)
Assignee:	Albert Einstein College of Medicine of Yeshiva University (Bronx, NY)
Application Number:	12/788,015
Patent Claims:	1. A method for reducing the likelihood of developing a skin rash secondary to an anti-epidermal growth factor (EGFR) therapy in a subject in need of the therapy, the method comprising applying vitamin K3 to the skin of the subject prior to occurrence of the rash in an amount effective to reduce development of the rash. 2. The method of claim 1, wherein the vitamin K3 is applied to the face. 3. The method of claim 1, wherein the anti-EGFR therapy is treatment with an anti-EGFR antibody. 4. The method of claim 3, wherein the anti-EGFR antibody is cetuximab. 5. The method of claim 1, wherein the anti-EGFR therapy is treatment with an EGFR tyrosine kinase inhibitor. 6. The method of claim 5, wherein the EGFR tyrosine kinase inhibitor is gefitinib or erlotinib. 7. The method of claim 1, wherein the vitamin K3 activates EGFR. 8. The method of claim 1, wherein the vitamin K3 is formulated in a pharmaceutical formulation suitable for topical administration. 9. The method of claim 1, wherein the vitamin K3 is applied to the trunk. 10. The method of claim 1, comprising exposing skin cells to at least 0.01 mM vitamin K3.

Details for Patent 8,283,382

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2025-04-15
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2025-04-15